[go: up one dir, main page]

PE20050306A1 - Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf) - Google Patents

Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf)

Info

Publication number
PE20050306A1
PE20050306A1 PE2004000223A PE2004000223A PE20050306A1 PE 20050306 A1 PE20050306 A1 PE 20050306A1 PE 2004000223 A PE2004000223 A PE 2004000223A PE 2004000223 A PE2004000223 A PE 2004000223A PE 20050306 A1 PE20050306 A1 PE 20050306A1
Authority
PE
Peru
Prior art keywords
imidazol
tgf
inhibitors
growth factor
compounds
Prior art date
Application number
PE2004000223A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Andre Shavnya
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20050306A1 publication Critical patent/PE20050306A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE LAS FORMULAS (Ia) O (Ib), EN DONDE R1 ES UN ANILLO MONO, BI O POLICICLICO(C3-C20) SATURADO, INSATURADO O AROMATICO, OPCIONALMENTE SUSTITUIDO, QUE CONTIENE AL MENOS UN HETEROATOMO DE N, O Y S; CADA R3 ES H, HALO, HALOALQUILO(C1-C6), ALQUILO(C1-C6), ALQUENILO O ALQUILO(C2-C6), HETEROCICLILO(C5-C10), PERHALOALQUILO(C1-C6), ENTRE OTROS; S ES DE 1 A 5; R4 Y R6 TOMADOS JUNTO CON LOS ATOMOS A LOS QUE ESTAN UNIDOS FORMAN UN NUCLEO HETEROAROMATICO CONDENSADO. SON COMPUESTOS PREFERIDOS: 6-[2-(6-METILPIRIDIN-2-IL)IMIDAZOL[1,2-a]PIRIDIN-3-IL]QUINOLINA, 2-BENZO[1,3]DIOXOL-5-IL-3-(6-METILPIRIDINIL-2-IL)-1H-IMIDAZOL[1,2-a]IMIDAZOL, 1-METIL-6-[6-(6-METILPIRIDIN-2-IL)IMIDAZOL[2,1-b]TIAZOL-5-IL]-1H-BENZOTRIAZOL, 3-BENZOTIAZOL-6-IL-2-(6-METILPIRIDIN-2-IL)IMIDAZOL[1,2-a]PIRIMIDIN-7-ILAMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA RUTA SENALIZADORA DEL FACTOR DE CRECIMIENTO TRANSFORMANTE (TGF)-BETA Y SON UTILES EN EL TRATAMIENTO DEL CANCER Y ENFERMEDADES FIBROTICAS
PE2004000223A 2003-03-04 2004-03-01 Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf) PE20050306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45168303P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
PE20050306A1 true PE20050306A1 (es) 2005-05-16

Family

ID=32962623

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000223A PE20050306A1 (es) 2003-03-04 2004-03-01 Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf)

Country Status (14)

Country Link
US (2) US7417041B2 (es)
EP (1) EP1601676A2 (es)
JP (1) JP2006519249A (es)
AR (1) AR043449A1 (es)
BR (1) BRPI0407999A (es)
CA (1) CA2517933C (es)
GT (1) GT200400032A (es)
MX (1) MXPA05008148A (es)
NL (1) NL1025623C2 (es)
PA (1) PA8595001A1 (es)
PE (1) PE20050306A1 (es)
TW (1) TW200504069A (es)
UY (1) UY28214A1 (es)
WO (1) WO2004078110A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
DE60330362D1 (de) * 2002-09-18 2010-01-14 Pfizer Prod Inc Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
BR0314372A (pt) * 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
JP2008516962A (ja) * 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
AU2006325706B2 (en) * 2005-12-16 2012-03-29 Novartis Ag Control of intraocular pressure using ALK5 modulation agents
PT1966214T (pt) * 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
CN101553224A (zh) * 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
US20080249305A1 (en) * 2007-03-27 2008-10-09 Calderwood David J Novel imidazole based heterocycles
CN103214482B (zh) 2007-04-03 2016-06-29 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
EP2162132A4 (en) * 2007-05-21 2013-01-16 Sgx Pharmaceuticals Inc Heterocyclic kinase modulators
WO2008150827A1 (en) * 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
EP2170337A4 (en) * 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
DK2193133T3 (en) 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
NZ595674A (en) 2009-04-02 2012-12-21 Ct Nac Investigaciones Oncologicas Cnio Imidazo[2,1-b][1,3,4]thiadiazole derivatives
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
US20120220581A1 (en) 2009-10-30 2012-08-30 Janssen-Cilag, S.A. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
MX2012006994A (es) 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2723744B1 (en) 2011-06-27 2016-03-23 Janssen Pharmaceutica, N.V. 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
PT2731949T (pt) 2011-07-13 2018-06-15 Tiumbio Co Ltd Imidazóis substituídos com 2-piridilo como inibidores de alk5 e/ou alk4
EP2855665B8 (en) 2012-05-30 2019-09-25 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
US20140120116A1 (en) * 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP6789941B2 (ja) * 2014-11-21 2020-11-25 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｔｇｆ−ベータ阻害剤としての縮合イミダゾール誘導体
TW201630907A (zh) * 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
SG11201707346RA (en) 2015-03-11 2017-10-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EP3387112A4 (en) 2015-12-07 2019-08-21 BioTime, Inc. METHOD FOR RECONNECTING BROWN FAT CELLS DERIVED FROM VARIOUS PLURIPOTENT STEM CELLS
JP2019515041A (ja) 2016-05-06 2019-06-06 メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗菌剤ならびにそれを作製および使用する方法
SG11202104331YA (en) 2018-12-11 2021-05-28 Theravance Biopharma R&D Ip Llc Naphthyridine and quinoline derivatives useful as alk5 inhibitors
AU2020385400A1 (en) * 2019-11-22 2022-06-09 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
ZW24186A1 (en) 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4719218A (en) * 1985-12-12 1988-01-12 Smithkline Beckman Corporation Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
MY103766A (en) * 1987-09-02 1993-09-30 Smithkline Beckman Corp Pyrrolo[1,2-a]imidazole and imidazo[1,2-a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6465493B1 (en) 1999-04-09 2002-10-15 Smithkline Beecham Corporation Triarylimidazoles
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ES2237671T3 (es) 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
DE60207390T2 (de) 2001-03-09 2006-07-20 Pfizer Products Inc., Groton Entzündungshemmende benzimidazolverbindungen
HUP0303415A2 (hu) 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
ATE304009T1 (de) 2001-04-04 2005-09-15 Pfizer Prod Inc Neue benzotriazole mit entzündungshemmender wirkung
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
CA2499429C (en) 2002-09-18 2010-09-21 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
BR0314286A (pt) 2002-09-18 2005-08-02 Pfizer Prod Inc Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf)
BR0314372A (pt) 2002-09-18 2005-07-19 Pfizer Prod Inc Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)
DE60330362D1 (de) * 2002-09-18 2010-01-14 Pfizer Prod Inc Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
EP1542685A1 (en) * 2002-09-18 2005-06-22 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors

Also Published As

Publication number Publication date
WO2004078110A3 (en) 2004-11-11
NL1025623A1 (nl) 2004-09-07
TW200504069A (en) 2005-02-01
CA2517933A1 (en) 2004-09-16
NL1025623C2 (nl) 2005-03-14
JP2006519249A (ja) 2006-08-24
PA8595001A1 (es) 2004-09-28
WO2004078110A2 (en) 2004-09-16
GT200400032A (es) 2004-10-21
US20040176390A1 (en) 2004-09-09
EP1601676A2 (en) 2005-12-07
US7417041B2 (en) 2008-08-26
UY28214A1 (es) 2004-09-30
CA2517933C (en) 2009-05-12
AR043449A1 (es) 2005-07-27
US20080275235A1 (en) 2008-11-06
BRPI0407999A (pt) 2006-03-07
MXPA05008148A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
PE20050306A1 (es) Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf)
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20030922A1 (es) Derivados de piridina y quinolina
AR029803A1 (es) Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
MA30053B1 (fr) Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
UY24655A1 (es) Derivados 6,6- ó 6,7-biciclicos sustituidos que contienen pirido o pirimido
CN104478865A (zh) 用于治疗例如癌症的疾病的取代的嘧啶
WO2010008847A2 (en) Pi3k/m tor inhibitors
CN102203098A (zh) 作为细胞增殖抑制剂的嘧啶并[5，4-d]嘧啶
PE20050074A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante
ATE424402T1 (de) Imidazopyridinverbindungen
TN2011000244A1 (en) Organic compounds
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
BRPI0519760A2 (pt) derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasse
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
WO2020106736A1 (en) Compounds and compositions for treating conditions associated with sting activity
EA201001178A1 (ru) 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2007044050A3 (en) 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
MX2023000580A (es) Derivados de 7-(piperidin-1-il)-4h-pirimido[1,2-b]piridazin-4-ona como moduladores alostericos positivos del receptor muscarinico m4 de la acetilcolina.
DE60230683D1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
EA032384B1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta

Legal Events

Date Code Title Description
FA Abandonment or withdrawal